Company profile
Senya Therapeutics
Harnessing LRG1 for long-term health
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNjc3OTgwN2FkaXF6a2N4
Published 22 Sep 2024 11:53
RESOLUTIONS | Transaction WUQ4TlFIVFRhZGlxemtjeA | Paper/PDF filed
Published 08 Aug 2024 08:18
Company registered at Companies House
The company has been set up to advance the development of the LRG1 blocking antibody Magacizumab, and also its Fab fragment (that we term MagaFab) specifically for use in ocular indications. The first objectives of the company are to establish that MagaFab is tolerated in the eye and is therefore suitable for onward development towards early stage clinical trials. The company operates under the name PanAngium Therapeutics, and as of early 2021 has a CEO who is leading the search for investment.
The company was formed at the start of 2019, so no notable impacts just yet.
1 May 2024 to 30 Apr 2025
LRG1 is a secreted glycoprotein that plays a key role in a range of highly prevalent chronic diseases by promoting vascular dysfunction, fibrosis and uncontrolled cell proliferation. Mounting evidence shows its involvement in diseases such as chronic kidney disease (CKD) which affects over 800 million people globally with significant morbidity and mortali...
